MX2011007384A - Terapias de combinacion para trastornos neoplásticos. - Google Patents

Terapias de combinacion para trastornos neoplásticos.

Info

Publication number
MX2011007384A
MX2011007384A MX2011007384A MX2011007384A MX2011007384A MX 2011007384 A MX2011007384 A MX 2011007384A MX 2011007384 A MX2011007384 A MX 2011007384A MX 2011007384 A MX2011007384 A MX 2011007384A MX 2011007384 A MX2011007384 A MX 2011007384A
Authority
MX
Mexico
Prior art keywords
neoplastic disorders
combination therapies
neoplastic
disorders
compositions
Prior art date
Application number
MX2011007384A
Other languages
English (en)
Inventor
Denis Drygin
Caroline B Ho
Joshua R Bliesath
Christopher B Proffitt
Kenna Anderes
Sean O'brien
Original Assignee
Cylene Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cylene Pharmaceuticals Inc filed Critical Cylene Pharmaceuticals Inc
Publication of MX2011007384A publication Critical patent/MX2011007384A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente solicitud generalmente está dirigida a compuestos, composiciones y métodos para terapia de combinación para el tratamiento de trastornos neoplásticos.
MX2011007384A 2009-01-08 2009-06-10 Terapias de combinacion para trastornos neoplásticos. MX2011007384A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14328209P 2009-01-08 2009-01-08
PCT/US2009/046948 WO2010080170A1 (en) 2009-01-08 2009-06-10 Combination therapies for neoplastic disorders

Publications (1)

Publication Number Publication Date
MX2011007384A true MX2011007384A (es) 2011-12-14

Family

ID=40973134

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011007384A MX2011007384A (es) 2009-01-08 2009-06-10 Terapias de combinacion para trastornos neoplásticos.

Country Status (13)

Country Link
EP (1) EP2381942A1 (es)
JP (1) JP2012514638A (es)
KR (1) KR20110116153A (es)
CN (1) CN102341107A (es)
AU (1) AU2009336141A1 (es)
BR (1) BRPI0924041A2 (es)
CA (1) CA2749261A1 (es)
IL (1) IL213969A0 (es)
MX (1) MX2011007384A (es)
RU (1) RU2011133093A (es)
SG (1) SG172922A1 (es)
WO (1) WO2010080170A1 (es)
ZA (1) ZA201105755B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100173013A1 (en) * 2009-01-08 2010-07-08 Denis Drygin Treatment of neoplastic disorders using combination therapies
CN114869903A (zh) * 2022-06-14 2022-08-09 苏天生命科技(苏州)有限公司 巴弗洛霉素a1在优化急性淋系白血病化疗组合药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2061765T3 (en) * 2006-09-01 2015-01-26 Senhwa Biosciences Inc Serine-threonine protein kinase AND PARP-MODULATOR
EP2137535B1 (en) * 2007-04-13 2015-06-03 Dana-Farber Cancer Institute, Inc. Receptor tyrosine kinase profiling

Also Published As

Publication number Publication date
AU2009336141A1 (en) 2011-08-11
RU2011133093A (ru) 2013-02-20
JP2012514638A (ja) 2012-06-28
EP2381942A1 (en) 2011-11-02
CN102341107A (zh) 2012-02-01
WO2010080170A1 (en) 2010-07-15
SG172922A1 (en) 2011-08-29
ZA201105755B (en) 2012-04-25
KR20110116153A (ko) 2011-10-25
CA2749261A1 (en) 2010-07-15
IL213969A0 (en) 2011-08-31
BRPI0924041A2 (pt) 2016-01-26

Similar Documents

Publication Publication Date Title
AU2011328009A8 (en) Compounds and methods for treating pain
MX2012000949A (es) Terapias de combinacion con moduladores de ck2.
MY173994A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
MX2011007930A (es) Conjugados de insulina cristalina.
MX2019008122A (es) Derivados de aminas heterociclicas que inhiben la transduccion de se?al mediada por cinasa asociada con el receptor de interleucina-1.
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
MX351464B (es) El uso de un agonista del receptor 8 tipo toll para el tratamiento de enfermedades alérgicas.
MY165620A (en) Cyclopropylamines as lsd1 inhibitors
MX343135B (es) Compuestos de tipo fumagilol y métodos de realización y uso de los mismos.
JO3199B1 (ar) مركبات 5- فلورو-1h- بيرازولوبيريدينات مستبدلة واستخدامها
IN2012DN02081A (es)
NZ707778A (en) Therapeutic compounds and compositions and their use as pkm2 modulators
IN2012DN00624A (es)
MX2010007490A (es) Preparacion de derivados de sulfamida.
GB2503852A (en) Compounds for the treatment of neuropsychiatric disorders
MX2012004078A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
TN2012000610A1 (en) Heterocyclic compounds, their preparation and their therapeutic application
MX2012010212A (es) Terapias inhibidoras de autofagia basadas en tioxantona para tratar el cancer.
MX2013002261A (es) N-fenetiltriazolonacetamidas sustituidas y su uso.
WO2011116351A3 (en) Methods and compositions for the treatment of cancer
MX2011007384A (es) Terapias de combinacion para trastornos neoplásticos.
MX2013006526A (es) Dosis de los derivados de arilsulfonamida.
NZ750581A (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
NZ629475A (en) Pharmaceutical composition comprising benzyl alcohol for the treatment of migraines

Legal Events

Date Code Title Description
FA Abandonment or withdrawal